ClinicalTrials.gg
RecruitingNCT05819138T1-DISCOUpdated Mar 4, 2026

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

A Phase 3 interventional study of Semaglutide Pen Injector and Placebo in Diabetes Mellitus, Type 1, sponsored by University of Colorado, Denver. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by University of Colorado, Denver · Phase 3, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing semaglutide in Diabetes Mellitus, Type 1 — 11 open to participants now, 12 under way, 7 of them phase 3. Semaglutide · Diabetes Mellitus, Type 1.

Planned enrollment
8th of 16
60 · median 60
Started
2023
with 2 others
Phase 3
4 of 16
4 open now
Primary completion
2027-10
later than 5 of 11 live
Registered
7th of 16
by date
Lead sponsor
1 of 16
University of Colorado, Denver

Among the 16 studies testing semaglutide in Diabetes Mellitus, Type 1, this one is the 8th largest by planned enrollment, is one of 3 that started in 2023, is one of 4 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 7th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

11 of the 16 studies testing semaglutide in Diabetes Mellitus, Type 1 are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing semaglutide in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-49 years
  • 1) T1D diagnosis defined as positive T1D-associated antibody(ies) or 2) a clinical diagnosis of T1D plus insulin requirement since diagnosis
  • Insulin pump or automated insulin delivery systems
  • Estimated (eGFR) ≥ 45 ml/min/1.73m2
  • Stable doses of drugs altering cardiovascular and renal function (e.g., Angiotensin-Converting Enzyme Inhibitor (ACEi), Angiotensin Receptor Blocker (ARB), statins, diuretics)
  • 20-45 kg/m2
  • Adequate method for females

Exclusion criteria

Exclusion Criteria:

  • >9%, recent diabetic ketoacidosis (DKA) or hospitalization
  • Major congenital heart disease, anemia, severe non-proliferative retinopathy, proliferative retinopathy
  • History/family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN2), pancreatitis
  • Current/planned pregnancy or nursing
  • Uncontrolled thyroid disease or hypertension (HTN) (≥ 160/100 mm Hg despite optimal therapy)
  • Use of other non-insulin diabetes medications, insulin sensitizing medications, or systemic in past 3 months
  • Use of atypical antipsychotics
  • Significant systemic illness such as cancer
  • Shellfish/iodine allergy (only exclusionary to iohexol clearance procedure)
  • MRI or PAH (only exclusionary to MRI and PAH procedures), GLP-1RA allergy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Semaglutide

    Participants will receive 0.25 mg once weekly semaglutide injection for 4 weeks. Participants will receive 0.50 mg once weekly semaglutide injection for 4 weeks. Participants will receive 1.0 mg once weekly semaglutide injection for 6 months.

    Drug: Semaglutide Pen Injector

  • Placebo comparator
    Placebo

    Participants will receive 0.25 mg once weekly placebo injection for 4 weeks. Participants will receive 0.50 mg once weekly placebo injection for 4 weeks. Participants will receive 1.0 mg once weekly placebo injection for 6 months.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Ascending Aortic Pulse Wave Velocity (AA PWV)

    AA PWV is a measure of central arterial stiffness. A lower value indicates a better outcome.

    Time frame: Baseline, month 8

  2. Change in Carotid and Femoral Artery Pulse Wave Velocity (CF-PWV)

    CF-PWV is a measure of peripheral arterial stiffness. A lower value indicates a better outcome.

    Time frame: Baseline, month 8

  3. Change in Carotid and Radial Artery Pulse Wave Velocity (CR-PWV)

    CR-PWV is a measure of peripheral arterial stiffness. A lower value indicates a better outcome.

    Time frame: Baseline, month 8

Secondary outcomes

  1. Change in Insulin Sensitivity

    Insulin Sensitivity is a measure of how well the body responds insulin. A higher value indicates a better outcome; a lower value indicates a worse outcome.

    Time frame: Baseline, month 8

  2. Change in Renal Vascular Resistance (RVR)

    RVR is a measure of mean arterial pressure to renal blood flow. A higher value indicates a worse outcome.

    Time frame: Baseline, month 8

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Oct 2027, 51 months after the start.

Of 108 phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Apr 19, 2023
StartActual
Jun 21, 2023
Primary completionEst.
Oct 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05819138
Responsible party
Sponsor
First posted
Apr 19, 2023
Start date
Jun 21, 2023
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Kyla Best
Contact
Kyla.Best@cuanschutz.edu
720-777-9500
Petter M Bjornstad, MD
principal investigator · University of Washington
Kristen Nadeau, MD, MS
principal investigator · University of Colorado, Denver

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion